Skip to main content

Veraxa Biotech AG - Post de-SPAC

VRXA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002079109

In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 2 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $599.6K in total; no superinvestor holds it.

Other share classesVRXAW

Key figures

Insider buysLast 90 days, $82.7K in total
2
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +8 vs. previous quarter
8
13F valueReported value at the end of Q2 2026
$599.6K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding VRXA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding VRXA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Veraxa Biotech AG - Post de-SPAC insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 31, 2026 (view filing)4:10 PM ETAug 274 daysBaumann Oliver RolfDirectorPPurchase+50.0K$1.50+$75.0K+0.9%5.77M after
Aug 31, 2026 (view filing)4:10 PM ETAug 274 daysAntz Christoph RudigerChief Executive OfficerPPurchase+5.00K$1.53+$7.65KNew position5.00K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Veraxa Biotech AG - Post de-SPAC at the end of Q2 2026; share changes are against Q1 2026.

See all 8 holders
Institutions holding VRXA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
UBS Group AG157,237$295.6K0.00%+157,237New
Geode Capital Management, LLC119,767$225.2K0.00%+119,767New
HRT Financial LP18,874$35.0K0.00%+18,874New
Susquehanna International Group, LLP10,833$20.4K0.00%+10,833New
Picton Mahoney Asset Management175,000$19.3K0.00%+175,000New
Wolverine Asset Management LLC1,748$3.29K0.00%+1,748New
JPMorgan Chase & Co396$8590.00%+396New
Caitong International Asset Management Co., Ltd6$110.00%+6New